Comparative Pharmacology
Head-to-head clinical analysis: GENTAK versus U GENCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAK versus U GENCIN.
GENTAK vs U-GENCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
1-2 mg/kg IV every 8 hours for 7-10 days, targeting peak serum concentration of 6-10 mcg/mL and trough <2 mcg/mL.
None Documented
None Documented
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is 2-3 hours in patients with normal renal function; may prolong to 20-40 hours in end-stage renal disease
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Primarily renal (glomerular filtration) with 40-70% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%)
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic